201 related articles for article (PubMed ID: 32218488)
1. Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations.
Badaya A; Sasidhar YU
Sci Rep; 2020 Mar; 10(1):5501. PubMed ID: 32218488
[TBL] [Abstract][Full Text] [Related]
2. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
3. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
Chetty S; Bhakat S; Martin AJ; Soliman ME
J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
[TBL] [Abstract][Full Text] [Related]
4. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
C S V; Tamizhselvi R; Munusami P
J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
[TBL] [Abstract][Full Text] [Related]
5. Drug pressure selected mutations in HIV-1 protease alter flap conformations.
Galiano L; Ding F; Veloro AM; Blackburn ME; Simmerling C; Fanucci GE
J Am Chem Soc; 2009 Jan; 131(2):430-1. PubMed ID: 19140783
[TBL] [Abstract][Full Text] [Related]
6. Conformational and dynamical basis for cross-reactivity observed between anti HIV-1 protease antibody with protease and an epitope peptide from it.
Badaya A; Sasidhar YU
Int J Biol Macromol; 2018 Oct; 118(Pt B):1696-1707. PubMed ID: 29990556
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics and ligand docking of a hinge region variant of South African HIV-1 subtype C protease.
Zondagh J; Balakrishnan V; Achilonu I; Dirr HW; Sayed Y
J Mol Graph Model; 2018 Jun; 82():1-11. PubMed ID: 29625416
[TBL] [Abstract][Full Text] [Related]
8. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of HIV protease by monoclonal antibodies.
Rezacova P; Brynda J; Fabry M; Horejsi M; Stouracova R; Lescar J; Chitarra V; Riottot MM; Sedlacek J; Bentley GA
J Mol Recognit; 2002; 15(5):272-6. PubMed ID: 12447903
[TBL] [Abstract][Full Text] [Related]
10. How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.
Appadurai R; Senapati S
Biochemistry; 2017 Jun; 56(23):2907-2920. PubMed ID: 28505418
[TBL] [Abstract][Full Text] [Related]
11. Exploring molecular mechanism of allosteric inhibitor to relieve drug resistance of multiple mutations in HIV-1 protease by enhanced conformational sampling.
Chen J; Peng C; Wang J; Zhu W
Proteins; 2018 Dec; 86(12):1294-1305. PubMed ID: 30260044
[TBL] [Abstract][Full Text] [Related]
12. Studies on adaptability of binding residues and flap region of TMC-114 resistance HIV-1 protease mutants.
Purohit R; Rajendran V; Sethumadhavan R
J Biomol Struct Dyn; 2011 Aug; 29(1):137-52. PubMed ID: 21696230
[TBL] [Abstract][Full Text] [Related]
13. Anti-HIV proteinase monoclonal antibody F11.2.32 that inhibits enzyme activity.
Stouracova R; Lescar J; Brynda J; Riottot MM; Chitarra V; Fabry M; Horejsi M; Rezacova P; Bentley G; Sedlacek J
Gen Physiol Biophys; 1998 Jun; 17 Suppl 1():6-8. PubMed ID: 9789741
[No Abstract] [Full Text] [Related]
14. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
Seibold SA; Cukier RI
Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
[TBL] [Abstract][Full Text] [Related]
15. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
[TBL] [Abstract][Full Text] [Related]
16. Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.
Maphumulo SI; Halder AK; Govender T; Maseko S; Maguire GEM; Honarparvar B; Kruger HG
Chem Biol Drug Des; 2018 Nov; 92(5):1899-1913. PubMed ID: 30003668
[TBL] [Abstract][Full Text] [Related]
17. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
Meher BR; Wang Y
J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
[TBL] [Abstract][Full Text] [Related]
18. Studies on flexibility and binding affinity of Asp25 of HIV-1 protease mutants.
Purohit R; Rajasekaran R; Sudandiradoss C; George Priya Doss C; Ramanathan K; Rao S
Int J Biol Macromol; 2008 May; 42(4):386-91. PubMed ID: 18367244
[TBL] [Abstract][Full Text] [Related]
19. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
[TBL] [Abstract][Full Text] [Related]
20. Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.
Karnati KR; Wang Y
J Mol Graph Model; 2019 Nov; 92():112-122. PubMed ID: 31351319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]